SCHEMBL3632875

SCHEMBL3632875

COC1(OC)CC(C(=O)O)C1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APLNR P35414 1/20 0.54
CYP2C19 P33261 4/20 0.52
CYP1A2 P05177 3/20 0.44
ALOX15 P16050 2/20 0.44
ALDH1A1 P00352 2/20 0.44
KDM4E B2RXH2 1/20 0.44
GRM4 Q14833 6/20 0.34
GRM2 Q14416 2/20 0.34
GRM3 Q14832 2/20 0.34
TSHR P16473 2/20 0.34
TDP1 Q9NUW8 2/20 0.34
GRM8 O00222 2/20 0.34
GRM6 O15303 2/20 0.34
LMNA P02545 1/20 0.34
GRM5 P41594 1/20 0.34
MTOR P42345 1/20 0.34
GRM1 Q13255 1/20 0.34
PLCB1 Q9NQ66 1/20 0.34
SLC6A4 P31645 1/20 0.33
MAPT P10636 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9955907 0.91 APLNR (0.50) APLNRCYP2C19CYP1A2ALOX15ALDH1A1
SCHEMBL28635475 0.82 GRM2 (0.47) APLNRCYP2C19CYP1A2ALOX15ALDH1A1
SCHEMBL13818120 0.80 APLNR (0.32) APLNRALDH1A1
SCHEMBL449125 0.78 CHRNB2 (0.42) CYP1A2
SCHEMBL22609983 0.78 SMN1; SMN2 (0.34) APLNRKDM4EMAPTKMT2ACYP2D6
SCHEMBL19284443 0.78 APLNR (0.58) APLNRCYP2C19CYP1A2ALOX15ALDH1A1
SCHEMBL19284442 0.78 APLNR (0.58) APLNRCYP2C19CYP1A2ALOX15ALDH1A1
SCHEMBL15334702 0.76 LMNA (0.41) APLNRCYP2C19CYP1A2ALOX15ALDH1A1
SCHEMBL24693063 0.75
SCHEMBL31415916 0.75 HDAC8 (0.41)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4562001-A1 SUBSTITUTED PYRIDINE DERIVATIVES AS SARM1 INHIBITORS Nura Bio, Inc. (US) 2025-06-04 EP disclosed
EP-3541804-B1 CYCLOALKYL SUBSTITUTED TRIAZOLE COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR AMGEN INC (US) 2025-01-22 EP disclosed
US-20240417405-A1 Substituted Spiro Derivatives JANSSEN PHARMACEUTICA NV (BE) 2024-12-19 US disclosed
WO-2024114658-A1 SUBSTITUTED 1-PHENYL-3, 4-DIHYDROPYRIDO [3, 4-D] PYRIMIDIN-2-ONE DERIVATIVES JANSSEN PHARMACEUTICA NV (BE) 2024-06-06 WO disclosed
EP-4347588-A1 SUBSTITUTED PHENYL-1H-PYRROLO[2, 3-C]PYRIDINE DERIVATIVES JANSSEN Pharmaceutica NV (BE) 2024-04-10 EP disclosed
CN-117730081-A Substituted spirocyclic derivatives 詹森药业有限公司 2024-03-19 CN disclosed
EP-4334310-A1 SUBSTITUTED SPIRO DERIVATIVES JANSSEN Pharmaceutica NV (BE) 2024-03-13 EP disclosed
EP-4334320-A1 SUBSTITUTED SPIRO DERIVATIVES JANSSEN Pharmaceutica NV (BE) 2024-03-13 EP disclosed
WO-2024026368-A1 SUBSTITUTED PYRIDINE DERIVATIVES AS SARM1 INHIBITORS NURA BIO, INC. (US) 2024-02-01 WO disclosed
CN-117396476-A Substituted phenyl-1H-pyrrolo [2,3-c ] pyridine derivatives 詹森药业有限公司 2024-01-12 CN disclosed
WO-2018167176-A1 FUSED PENTACYCLIC IMIDAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY UCB BIOPHARMA SPRL (BE) 2018-09-20 WO disclosed
EP-3055306-A1 OXAZOLIDINONES AS MODULATORS OF MGLUR5 Bristol-Myers Squibb Company (US) 2016-08-17 EP disclosed
WO-2015054103-A1 OXAZOLIDINONES AS MODULATORS OF MGLUR5 BRISTOL-MYERS SQUIBB COMPANY (US) 2015-04-16 WO disclosed
EP-2854797-A2 CHROMANE COMPOUNDS Comentis, Inc. (US) 2015-04-08 EP disclosed
WO-2013181202-A2 CHROMANE COMPOUNDS ASTELLAS PHARMA INC. (JP) 2013-12-05 WO disclosed
EP-2155716-A2 SUBSTITUTED HETEROCYCLIC DERIVATIVES AND COMPOSITIONS AND THEIR PHARMACEUTICAL USE AS ANTIBACTERIALS Pfizer Inc. (US) 2010-02-24 EP disclosed
WO-2008139288-A2 SUBSTITUTED HETEROCYCLIC DERIVATIVES AND COMPOSITIONS AND THEIR PHARMACEUTICAL USE AS ANTIBACTERIALS PFIZER INC. (US) 2008-11-20 WO disclosed
WO-2001022919-A2 SPIRO[BICYCLIC -AZACYCLOALKYL AND -CYCLOALKYL] DERIVATIVES AND USES THEREOF MERCK & CO., INC. (US) 2001-04-05 WO disclosed
EP-0923536-A1 ARYLCYCLOALKANE CARBOXYLIC ESTERS, THEIR USE, PHARMACEUTICAL COMPOSITIONS AND PREPARATION Pharmacia & Upjohn Aktiebolag (SE) 1999-06-23 EP disclosed
WO-1998004517-A1 ARYLCYCLOALKANE CARBOXYLIC ESTERS, THEIR USE, PHARMACEUTICAL COMPOSITIONS AND PREPARATION PHARMACIA & UPJOHN AB (SE) 1998-02-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240417405-A1 Substituted Spiro Derivatives BMI1, MLLT1, MLLT3 APLNR 2339/4885CYP2C19 4250/4885CYP1A2 3957/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.